399 related articles for article (PubMed ID: 17478065)
1. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles.
Dreis S; Rothweiler F; Michaelis M; Cinatl J; Kreuter J; Langer K
Int J Pharm; 2007 Aug; 341(1-2):207-14. PubMed ID: 17478065
[TBL] [Abstract][Full Text] [Related]
2. Photosensitizer loaded HSA nanoparticles. I: Preparation and photophysical properties.
Wacker M; Chen K; Preuss A; Possemeyer K; Roeder B; Langer K
Int J Pharm; 2010 Jun; 393(1-2):253-62. PubMed ID: 20417701
[TBL] [Abstract][Full Text] [Related]
3. Novel method of doxorubicin-SPION reversible association for magnetic drug targeting.
Munnier E; Cohen-Jonathan S; Linassier C; Douziech-Eyrolles L; Marchais H; Soucé M; Hervé K; Dubois P; Chourpa I
Int J Pharm; 2008 Nov; 363(1-2):170-6. PubMed ID: 18687392
[TBL] [Abstract][Full Text] [Related]
4. Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles.
Azarmi S; Tao X; Chen H; Wang Z; Finlay WH; Löbenberg R; Roa WH
Int J Pharm; 2006 Aug; 319(1-2):155-61. PubMed ID: 16713150
[TBL] [Abstract][Full Text] [Related]
5. Freeze drying of human serum albumin (HSA) nanoparticles with different excipients.
Anhorn MG; Mahler HC; Langer K
Int J Pharm; 2008 Nov; 363(1-2):162-9. PubMed ID: 18672043
[TBL] [Abstract][Full Text] [Related]
6. New doxorubicin-loaded phospholipid microbubbles for targeted tumor therapy: Part I--Formulation development and in-vitro characterization.
Tinkov S; Winter G; Coester C; Bekeredjian R
J Control Release; 2010 Apr; 143(1):143-50. PubMed ID: 20060861
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of water-soluble albumin-bound curcumin nanoparticles with improved antitumor activity.
Kim TH; Jiang HH; Youn YS; Park CW; Tak KK; Lee S; Kim H; Jon S; Chen X; Lee KC
Int J Pharm; 2011 Jan; 403(1-2):285-91. PubMed ID: 21035530
[TBL] [Abstract][Full Text] [Related]
8. Human serum albumin (HSA) nanoparticles: reproducibility of preparation process and kinetics of enzymatic degradation.
Langer K; Anhorn MG; Steinhauser I; Dreis S; Celebi D; Schrickel N; Faust S; Vogel V
Int J Pharm; 2008 Jan; 347(1-2):109-17. PubMed ID: 17681686
[TBL] [Abstract][Full Text] [Related]
9. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
10. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery.
Zhang C; Zhao L; Dong Y; Zhang X; Lin J; Chen Z
Eur J Pharm Biopharm; 2010 Sep; 76(1):10-6. PubMed ID: 20472060
[TBL] [Abstract][Full Text] [Related]
11. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: focus on cardio- and testicular toxicity.
Pereverzeva E; Treschalin I; Bodyagin D; Maksimenko O; Langer K; Dreis S; Asmussen B; Kreuter J; Gelperina S
Int J Pharm; 2007 Jun; 337(1-2):346-56. PubMed ID: 17306479
[TBL] [Abstract][Full Text] [Related]
12. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
Ko J; Park K; Kim YS; Kim MS; Han JK; Kim K; Park RW; Kim IS; Song HK; Lee DS; Kwon IC
J Control Release; 2007 Nov; 123(2):109-15. PubMed ID: 17894942
[TBL] [Abstract][Full Text] [Related]
13. [Preliminary study on preparation and pharmaceutic features of adrimycin-loaded human serum albumin microspheres].
Liu XB; Cai MY; Gong Y; Zhang ZR; Wei DP; Wang X; Li G
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jan; 35(1):107-9, 137. PubMed ID: 14981831
[TBL] [Abstract][Full Text] [Related]
14. Preparation and in Vitro Analysis of Human Serum Albumin Nanoparticles Loaded with Anthracycline Derivatives.
Kimura K; Yamasaki K; Nakamura H; Haratake M; Taguchi K; Otagiri M
Chem Pharm Bull (Tokyo); 2018; 66(4):382-390. PubMed ID: 29607904
[TBL] [Abstract][Full Text] [Related]
15. Oxidized phospholipid based pH sensitive micelles for delivery of anthracyclines to resistant leukemia cells in vitro.
Wang Y; Chen L; Ding Y; Yan W
Int J Pharm; 2012 Jan; 422(1-2):409-17. PubMed ID: 22037443
[TBL] [Abstract][Full Text] [Related]
16. Photosensitizer loaded HSA nanoparticles II: in vitro investigations.
Preuss A; Chen K; Hackbarth S; Wacker M; Langer K; Röder B
Int J Pharm; 2011 Feb; 404(1-2):308-16. PubMed ID: 21094228
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanoparticles consisted of cationic- and mannose-modified-albumins for dual-targeting in brain tumors.
Byeon HJ; Thao le Q; Lee S; Min SY; Lee ES; Shin BS; Choi HG; Youn YS
J Control Release; 2016 Mar; 225():301-13. PubMed ID: 26826308
[TBL] [Abstract][Full Text] [Related]
18. Preparation and optimization of doxorubicin-loaded albumin nanoparticles using response surface methodology.
Li L; Zhao X; Yang C; Hu H; Qiao M; Chen D
Drug Dev Ind Pharm; 2011 Oct; 37(10):1170-80. PubMed ID: 21449822
[TBL] [Abstract][Full Text] [Related]
19. Polymeric nanoparticles of cholesterol-modified glycol chitosan for doxorubicin delivery: preparation and in-vitro and in-vivo characterization.
Yu JM; Li YJ; Qiu LY; Jin Y
J Pharm Pharmacol; 2009 Jun; 61(6):713-9. PubMed ID: 19505361
[TBL] [Abstract][Full Text] [Related]
20. Entrapped doxorubicin nanoparticles for the treatment of metastatic anoikis-resistant cancer cells.
Lee H; Park S; Kim JB; Kim J; Kim H
Cancer Lett; 2013 May; 332(1):110-9. PubMed ID: 23348696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
